BD (Becton, Dickinson and Company), a main worldwide medical technology firm, and Edwards Lifesciences reported a conclusive arrangement under which BD will buy Edwards' critical Care product group (Critical Care), a worldwide forerunner in...
Massive Bio, an international leader in AI-driven oncology solutions, and Un Ensayo Para Mi (UEPM), Latin America's foremost clinical trial search portal, are pleased to announce an expanded collaboration. This agreement will expand Massive Bio's...
Moderna, Inc, a bitotechnology firm, reported that the US Food and Medication Organization (FDA) has sanctioned mRESVIA (mRNA-1345), a mRNA respiratory syncytial vaccine (RSV) immunization, to protect adults of 60 years and more established from...
Nxera Pharma Co. Ltd and PrecisionLife, the Causal AI medication organization, report the development of their key Research and development partnership into auto-immune disorders with the possibility to distinguish new medication focuses for the...
The growth-oriented biopharmaceutical company Xeris Biopharma Holdings, Inc., dedicated to enhancing patient lives through the development and commercialization of cutting-edge products across a spectrum of therapies, has released the topline...
The US Food and Drug Administration (FDA) has approved Onyda XR (clonidine hydrochloride), a once-daily extended-release oral suspension with nighttime dosing, for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric...
Foundation Medication, Inc., a trailblazer in molecular profiling for cancer, and Pharmaceuticals, Inc. reported an alliance to foster EFoundation Medication's tissue-based extensive genomic profiling test, FoundationOne CDx, as a companion...
Anti-diabetic drugs are driving the development in the pharmaceuticals market, posting the most noteworthy worth development of over ₹155 crore among the new brands introduced in the previous year .The respiratory section, which clocked deals of...
Enzene Biosciences has announced the formation of a new drug discovery branch. This broadens the CDMO's service offerings to the biotech industry and complements its EnzeneXTM-equipped biologics manufacturing location in the United States, which...
Piramal Pharma has recorded robust financial growth during the final quarter ended March 2024 and its united net benefit has taken a quantum bounce of 102% to Rs. 101 crore from Rs. 50 crore in the relating time of the year before. Its incomes...
.jpg)
